Arthrex told the Federal Circuit on Friday that the Patent Trial and Appeal Board’s invalidation of its suture patent cannot stand because it flouts a ruling from last month involving Qualcomm that restricted the prior art that can be used in inter partes reviews.
Arthrex Says Qualcomm Case Sinks Invalidity Ruling
Latest Intelligence
